Abstract
Advanced glycation end-products (AGEs) are heterogeneous groups of compounds that result from the non-enzymatic reaction of reducing sugars with free amino groups of biological molecules such as proteins, lipids, and nucleic acids. A large number of studies have been focused on AGEs metabolism, analysis, treatments, and their implications in the pathogenesis of diseases, especially in diabetes mellitus. Here, we review recent advances in the understanding of pathological complications caused by the production of AGEs. We provide an overview of the most important issues published within this area in last years; we also present the number of scientific papers related to AGEs available since 1950 until 2008 in the most important fields including metabolism, physiology, and pharmacology, thus as analytical methods for AGE detection and quantification and studies carried out in human body fluids. Data were collected from ovidSP.
Similar content being viewed by others
References
Kusunoki H, Miyata S, Ohara T et al (2003) Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 26:1889–1894
Chaikoff IL, Lachman GS (1933) Occurrence of cataracts in experimental pancreatic diabetes. Proc Soc Exp Biol Med 31:237–241
Colaco C (1997) Glycation and advanced glycation endproducts. In: The glycation hypothesis of atherosclerosis. Chapman & Hall, Austin, pp 57–61
Ronca G, Chiti R, Lucacchini A (1970) Separation of epsilon-carboxymethyl-lysine from methionine on 60-cm columns of ion-exchange resins. J Chromatogr 47:114–115
Nakayama T, Hayase F, Kato H (1980) Formation of e-(2-formyl-5-hydroxy-methyl-pyrrol-1-yl)-l-norleucine in the Maillard Reaction between d-glucose and l-lysine. Agric Biol Chem 44:1201–1202
Njore G, Fernandes A, Monnier VM (1998) Mechanism of formation of putative advanced glycosylation and product and protein cross-link 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazolone. J Biol Chem 263:10646–10652
Biemel K, Reihl O, Conrad J et al (2001) Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes: unraveling the structure of a pentosidine precursor. J Biol Chem 276:23405–23412
Nakamura K, Nakazawa Y, Ienaga K (1997) Acid-stable fluorescent advanced glycation end products: vesperlysine A, B and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose. Biochem Biophys Res Commun 232:227–230
Biemel K, Friedl D, Lederer M (2002) Identification and quantification of major Maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound. J Biol Chem 277:24907–24915
Horie K, Miyata T, Yasuda T et al (1997) Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer’s disease and aged neurons. Biochem Biophys Res Commun 236:327–332
Rietbrock J (2004) Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 53:131–142
Cooper ME (2004) Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 17:31S–38S
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
Schmidt AM, Yan SD, Yan SF et al (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498:99–111
Yeh CH, Sturgis L, Haidacher J et al (2001) Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50:1495–1504
Schwedler S, Schinzel R, Vaith P et al (2001) Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 59:S32–S36
Lin L, Park S, Lakatta EG (2009) RAGE signaling in inflammation and arterial aging. Front Biosci 14:1403–1413
Vlassara H, Brownlee M, Manogue K et al (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240:1546–1548
Zhang Y, Lin JX, Vilcek J (1990) Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol Cell Biol 10:3818–3823
Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1320
Soulis T, Thallas V, Youssef S et al (1997) Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40:619–628
Tanaka N, Yonekura H, Yamagishi S et al (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor through nuclear factor-κB, and by 17beta-estradiol through Sp1 in human vascular endothelial cells. J Biol Chem 275:25781–25790
Barile G, Pachydaki S, Tari SR et al (2005) The RAGE axis in early diabetic retinopathy. Invest Ophthalmol 46:2916–2924
Li YM, Mitsuhashi T, Wojciechowicz D et al (1996) Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 93:11047–11052
Miyazaki A, Nakamura H, Horiuchi S (2002) Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 12:258–262
Ohgami N, Nagai R, Ikemoto M et al (2002) CD36 serves as a receptor for AGEs. J Diabetes Complicat 16:56–59
Bierhaus A, Humpert PM, Morcos M et al (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876–886
Mene P, Festuccia F, Pugliese F (2003) Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus. Am J Cardiovasc Drugs 3:315–320
Giannoukakis N (2005) Pyridoxamine (BioStratum). Curr Opin Investig Drugs 6:410–418
Khalifah RG, Baynes JW, Hudson BG (1999) Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257:251–258
Vaitkevicius PV, Lane M, Spurgeon H et al (2001) A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 98:1171–1175
Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN et al (1998) Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95:4630–4634
Kass DA, Shapiro EP, Kawaguchi M et al (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104:1464–1470
Dan Q, Wong R, Chung SK et al (2004) Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion. Life Sci 76:445–459
Beyer-Mears A, Mistry K, Diecke FP et al (1996) Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. Pharmacology 52:292–302
Yamagishi S, Matsui T, Nakamura K et al (2005) Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 27:189–195
Duraisamy Y, Gaffney J, Slevin M et al (2003) Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine. Mol Cell Biochem 246:143–153
Méndez JD, Leal LI (2004) Inhibition of in vitro pyrraline formation by l-arginine and polyamines. Biomed Pharmacother 58:598–604
Méndez JD, Xie J, García-Pérez E (2007) Urea inhibits the in vitro formation of fluorescent advanced glycation end products. World Appl Sci J 2:90–98
Thomas MC, Baynes JW, Thorpe SR et al (2005) The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6:453–474
Ruiz-Ortega M, Lorenzo O, Ruperez M et al (2000) ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect. Nephrol Dial Transpl 15:561–565
Wolf G, Neilson EG (1993) Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531–1540
Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869
Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259
Forbes JM, Cooper ME, Thallas V et al (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274–3282
Goldin A, Beckman JA, Schmidt AM et al (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597–605
Yamagishi S, Nakamura K, Matsui T et al (2006) Cardiovascular disease in diabetes. Mini-Rev Org Chem 6:313–318
Kaneko M, Bucciarelli L, Hwang YC et al (2005) Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci 1043:702–719
Yamagishi S, Inagaki Y, Okamoto T et al (2002) Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 277:20309–20315
Dworkin LD, Ichikawa I, Brenner BM et al (1983) Hormonal modulation of glomerular function. Am J Physiol 244:F95–F104
Silbiger S, Crowley S, Shan Z et al (1993) Nonenzymatic elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int 43:853–864
Brownlee M (1994) Glycation and diabetic complications. Diabetes 43:836–841
Yamagishi S, Takeuchi M, Makita Z (2001) Advanced glycation end products and the pathogenesis of diabetic nephropathy. In: Tomino Y (ed) Type-2 diabetic nephropathy in Japan. From bench to bedside. Contrib Nephrol 134:30–35
Yamagishi S, Inagaki Y, Okamoto T et al (2003) Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 63:464–473
Sharma K, Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44:1139–1146
Cogan DG, Toussaint D, Kuwabara T (1961) Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmo 66:366–378
Mandarino LJ (1992) Current hypotheses for the biochemical basis of diabetic retinopathy. Diabetes Care 15:1892–1901
Frank RN (1990) On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology 98:586–593
Herman IM, D’Amore PA (1985) Microvascular pericytes contain muscle and nonmuscle actins. J Cell Biol 101:43–52
Joyce NC, Haire MF, Palade GE (1985) Contractile proteins in pericytes. II. Immunocytochemical evidence for the presence of two isomyosins in graded concentrations. J Cell Biol 100:1387–1395
Yamagishi S, Hsu CC, Taniguchi M et al (1995) Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. Biochem Biophys Res Commun 213:681–687
Yamagishi S, Amano S, Inagaki Y et al (2002) Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 290:973–978
Moore CR, Wang R (2006) Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 8:675–684
Andersson KE, Wagner G (1995) Physiology of penile erection. Physiol Rev 75:191–236
Giuliano F, Rampin O (2000) Central control of erection and its pharmacological modification. Curr Opin Urol 10:629–633
Melis MR, Argiolas A (1997) Role of central nitric oxide in the control of penile erection and yawning. Prog Neuro-Psychopharmacol Biol Psychiatry 21:899–922
Sell DR, Monnier VM (1989) Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 264:21597–21602
Nagaraj RH, Shipanova IN, Faust FM (1996) Protein cross-linking by the Maillard reaction. J Biol Chem 271:19338–19345
Kalousova M, Zima T, Malbohan IM et al (2002) Determination of advanced glycation end products. Sb Lek 103:427–434
Amanoa S, Kajia Y, Oshikaa T et al (2001) Advanced glycation end products in human optic nerve head. Br J Ophthalmol 85:52–55
Sasaki N, Fukatsu R, Tsuzuki K et al (1998) Advanced glycation end products in Alzheimer’s disease and other neurodegenerative diseases. Am J Pathol 153:1149–1155
Petrovic R, Futas J, Chandoga J et al (2005) Rapid and simple method for determination of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in urine using gas chromatography/mass spectrometry. Biomed Chromatogr 19:649–654
Ahmed N, Babaei-Jadidi R, Howell SK et al (2005) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590–1603
Thornalley PJ (2005) Measurement of protein glycation, glycated peptides, and glycation free adducts. Perit Dial Int 25:522–533
Kislinger T, Humeny A, Peich CC et al (2005) Analysis of protein glycation products by MALDI-TOF/MS. Ann N Y Acad Sci 1043:249–259
Shimada S, Tanaka Y, Ohmura C et al (2005) N-(carboxymethyl)valine residues in hemoglobin (CMV-Hb) reflect accumulation of oxidative stress in diabetic patients. Diabetes Res Clin Pract 69:272–278
Schalkwijk CG, Wee PM, Stehouwer CD (2005) Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate : Possible role of AGE peptide-associated endothelial dysfunction. Ann N Y Acad Sci 1043:662–670
Nagai R, Deemer EK, Brock JW et al (2005) Effect of glucose concentration on formation of AGEs in erythrocytes in vitro. Ann N Y Acad Sci 1043:146–150
Yamagishi S, Nakamura K, Inoue H et al (2005) Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer’s disease. Med Hypotheses 64:1205–1207
Konings CJ, Schalkwijk CG, van der Sande FM et al (2005) Influence of icodextrin on plasma and dialysate levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine. Perit Dial Int 25:591–595
Peppa M, Brem H, Cai W et al (2006) Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 26:430–436
Bunn HF, Gabbay KH, Gallop PM (1978) The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200:21–27
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Méndez, J.D., Xie, J., Aguilar-Hernández, M. et al. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem 341, 33–41 (2010). https://doi.org/10.1007/s11010-010-0434-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-010-0434-5